Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma

Glenn J. Hanna, Vishwajith Sridharan, Danielle N. Margalit, Stephanie K. La Follette, Nicole G. Chau, Guilherme Rabinowits, Jochen H. Lorch, Robert I. Haddad, Roy B. Tishler, Karen Anderson, Jonathan D. Schoenfeld

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    BACKGROUND: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications. OBJECTIVE: Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC. METHODS: We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay. RESULTS:We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p = 0.03).When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p = 0.007). CONCLUSIONS: Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.

    Original languageEnglish (US)
    Pages (from-to)129-136
    Number of pages8
    JournalCancer Biomarkers
    Volume19
    Issue number2
    DOIs
    StatePublished - 2017

    Fingerprint

    Squamous Cell Carcinoma
    Antibodies
    Serum
    Saliva
    Therapeutics
    Chemoradiotherapy
    Proteins
    Immunoglobulin G
    Enzyme-Linked Immunosorbent Assay
    Recurrence
    Incidence

    Keywords

    • antibodies
    • HPV
    • oropharyngeal cancer
    • saliva

    ASJC Scopus subject areas

    • Oncology
    • Genetics
    • Cancer Research

    Cite this

    Hanna, G. J., Sridharan, V., Margalit, D. N., La Follette, S. K., Chau, N. G., Rabinowits, G., ... Schoenfeld, J. D. (2017). Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomarkers, 19(2), 129-136. https://doi.org/10.3233/CBM-160071

    Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. / Hanna, Glenn J.; Sridharan, Vishwajith; Margalit, Danielle N.; La Follette, Stephanie K.; Chau, Nicole G.; Rabinowits, Guilherme; Lorch, Jochen H.; Haddad, Robert I.; Tishler, Roy B.; Anderson, Karen; Schoenfeld, Jonathan D.

    In: Cancer Biomarkers, Vol. 19, No. 2, 2017, p. 129-136.

    Research output: Contribution to journalArticle

    Hanna, GJ, Sridharan, V, Margalit, DN, La Follette, SK, Chau, NG, Rabinowits, G, Lorch, JH, Haddad, RI, Tishler, RB, Anderson, K & Schoenfeld, JD 2017, 'Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma' Cancer Biomarkers, vol. 19, no. 2, pp. 129-136. https://doi.org/10.3233/CBM-160071
    Hanna, Glenn J. ; Sridharan, Vishwajith ; Margalit, Danielle N. ; La Follette, Stephanie K. ; Chau, Nicole G. ; Rabinowits, Guilherme ; Lorch, Jochen H. ; Haddad, Robert I. ; Tishler, Roy B. ; Anderson, Karen ; Schoenfeld, Jonathan D. / Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. In: Cancer Biomarkers. 2017 ; Vol. 19, No. 2. pp. 129-136.
    @article{85f751937e76418cbec21a58da6caa52,
    title = "Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma",
    abstract = "BACKGROUND: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications. OBJECTIVE: Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC. METHODS: We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay. RESULTS:We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p = 0.03).When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p = 0.007). CONCLUSIONS: Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.",
    keywords = "antibodies, HPV, oropharyngeal cancer, saliva",
    author = "Hanna, {Glenn J.} and Vishwajith Sridharan and Margalit, {Danielle N.} and {La Follette}, {Stephanie K.} and Chau, {Nicole G.} and Guilherme Rabinowits and Lorch, {Jochen H.} and Haddad, {Robert I.} and Tishler, {Roy B.} and Karen Anderson and Schoenfeld, {Jonathan D.}",
    year = "2017",
    doi = "10.3233/CBM-160071",
    language = "English (US)",
    volume = "19",
    pages = "129--136",
    journal = "Cancer Biomarkers",
    issn = "1574-0153",
    publisher = "IOS Press",
    number = "2",

    }

    TY - JOUR

    T1 - Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma

    AU - Hanna, Glenn J.

    AU - Sridharan, Vishwajith

    AU - Margalit, Danielle N.

    AU - La Follette, Stephanie K.

    AU - Chau, Nicole G.

    AU - Rabinowits, Guilherme

    AU - Lorch, Jochen H.

    AU - Haddad, Robert I.

    AU - Tishler, Roy B.

    AU - Anderson, Karen

    AU - Schoenfeld, Jonathan D.

    PY - 2017

    Y1 - 2017

    N2 - BACKGROUND: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications. OBJECTIVE: Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC. METHODS: We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay. RESULTS:We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p = 0.03).When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p = 0.007). CONCLUSIONS: Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.

    AB - BACKGROUND: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications. OBJECTIVE: Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC. METHODS: We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay. RESULTS:We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p = 0.03).When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p = 0.007). CONCLUSIONS: Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.

    KW - antibodies

    KW - HPV

    KW - oropharyngeal cancer

    KW - saliva

    UR - http://www.scopus.com/inward/record.url?scp=85020962747&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85020962747&partnerID=8YFLogxK

    U2 - 10.3233/CBM-160071

    DO - 10.3233/CBM-160071

    M3 - Article

    VL - 19

    SP - 129

    EP - 136

    JO - Cancer Biomarkers

    JF - Cancer Biomarkers

    SN - 1574-0153

    IS - 2

    ER -